Clinical trials: Psychotic Disorder
Schizophrenia, Schizoaffective Disorder
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT01981759
- Testing
- D-Cycloserine, Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- NYU Langone Health
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
The purpose of this study is to compare the efficacy of paliperidone palmitate and risperidone long acting injection (LAI) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT00604279
- Testing
- Paliperidone palmitate (R092670), Risperidone
- Where
- 8 sites in China
- Volunteers
- 452 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia Spectrum
Target Engagement for Oxytocin: Dose Ranging Study
This study will evaluate the effect of 8 doses of intranasal oxytocin or placebo on two proposed measures of target engagement in brain.
- Trial name
- R21Dose (NCT02498236)
- Testing
- Intranasal Oxytocin
- Volunteers
- 51 people
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizoaffective Disorder
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
Aim: To examine the efficacy of the combination of galantamine and memantine for the treatment of cognitive deficits in outpatients with schizophrenia.
- Trial name
- NCT02234752
- Testing
- Galantamine ER, Memantine XR
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia
Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia
- Trial name
- NCT00257192
- Testing
- Ziprasidone oral capsules
- Where
- 92 sites in United States, Colombia and 7 more
- Volunteers
- 284 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05741528
- Testing
- SEP-363856
- Where
- 16 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending intramuscular doses of MK-5720, and the safety and tolerability of multiple once-daily oral doses of MK-8189, in…
- Trial name
- NCT05953740
- Testing
- MK-5720, MK-8189
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
- Trial name
- NCT01760993
- Testing
- SPD489
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Shire
Schizophrenia, Cognition
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking.
- Conditions
- Schizophrenia, Cognition, Cigarette Smoking
- Trial name
- TDCSSCHIZ (NCT02128919)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects.
- Trial name
- NCT01423916
- Testing
- OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg)
- Where
- 8 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
The project is designed to address the following two primary aims: 1. To determine whether adjunctive oxytocin is superior to placebo for the treatment of persistent negative symptoms, as measured by the SANS total score, in…
- Trial name
- CIDAR-3 (NCT01012167)
- Testing
- Oxytocin, Galantamine
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Remediation of Auditory Recognition in Schizophrenia With tDCS
The purpose of this study is to determine whether transcranial direct current stimulation (tDCS), when combined with different forms of computer based training, improves the ability to discriminate small differences between…
- Trial name
- NCT02869334
- Testing
- Active Transcranial direct current stimulation (tDCS), Auditory Remediation, Control computer activities
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Varenicline Adjunctive Treatment in Schizophrenia
The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00492349
- Testing
- Varenicline
- Where
- 3 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
This study will recruit persons with schizophrenia or schizoaffective disorder and will use an oral glucose tolerance test to test the hypothesis that insulin resistance drives inflammation.
- Trial name
- NCT03818516
- Testing
- Oral Glucose Tolerance Test (OGTT)
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Schizophrenia
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions.
- Trial name
- NCT01312272
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Schizophrenia, Schizoaffective Disorder
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
The major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; and b) psychopathology…
- Trial name
- NCT00306475
- Testing
- Divalproex Sodium Extended-Release Tablets
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
Sodium Nitroprusside in Early Course Schizophrenia
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early…
- Trial name
- NCT04986072
- Testing
- Sodium Nitroprusside, 5% Dextrose solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
- Trial name
- NCT01469039
- Testing
- ALKS 9072
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 623 people
- Sponsor
- Alkermes, Inc.